DRUG KILLED: Roche has ended all testing of experimental drug dalcetrapib, meant to raise good cholesterol, after a late-stage study showed it didn't help patients.
CLASS EFFECT?: It's the second cholesterol drug of four in a class called CETP inhibitors to be scrapped. The other, Pfizer's torcetrapib, raised heart risks. They were planned to succeed the lucrative statin drugs, including Lipitor and Crestor.
STILL ON: Merck is continuing a huge, late-stage study of its CETP inhibitor, anacetrapib. Eli Lilly is about to start a late-stage study of its drug, evacetrapib.